Nasdaq mandates a clean slate for the SUPN ticker effective November 3, 2026, requiring data providers to map Indivior's historical performance to the new entity while excluding legacy Supernus Pharmaceuticals data.
Supernus Pharmaceuticals, Inc. (SUPN) is undergoing a merger with a subsidiary of Indivior Pharmaceuticals, Inc., leading to the suspension of the current SUPN ticker from Nasdaq. Following the merger, the Indivior entity will rebrand as Supernus, Inc. and assume the SUPN ticker symbol effective November 3, 2026. This represents a corporate restructuring where the ticker symbol is being recycled for the surviving entity.
The ticker will be reused by the new Supernus, Inc. (formerly Indivior Pharmaceuticals, Inc.) following the merger.
No, Nasdaq explicitly states that history should not carry over from the old SUPN to the new SUPN; instead, the history from INDV should carry over to the new SUPN.
Nasdaq has confirmed that Indivior Pharmaceuticals will undergo a name and symbol change to Supernus, Inc. (SUPN) following shareholder approval of the merger on October 15, 2026. Market data redistributors are instructed to reset historical price data for the ticker, ensuring that the new SUPN listing reflects the history of Indivior rather than the legacy Supernus Pharmaceuticals entity.
Nasdaq requires that historical data from the old Supernus Pharmaceuticals be excluded, and instead, the history from Indivior (INDV) must be carried over to the new SUPN listing.
The name and symbol change to Supernus, Inc. (SUPN) becomes effective on Tuesday, November 3, 2026.